Clinical Trials Browser

dostarlimab × Gastrointestinal × Clear all

NCT06567782 2026-03-12

AZUR-4

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT06830239 2026-02-12

Superhero

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT07381777 2026-02-02

IMMUNOSTAR

Phase 2 Not yet recruiting

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT04165772 2026-01-23

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

Gastrointestinal

Rectal Neoplasms

NCT05855200 2026-01-23

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Phase 3 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1 Active not recruiting

BreastGastrointestinalGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT05723562 2026-01-08

AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT05277051 2025-12-19

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Phase 1 Recruiting

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07269249 2025-12-08

RW-NEDOS

Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

NCT04779151 2025-12-01

NIRADO

Phase 2 Terminated

GastrointestinalGenitourinaryHead & Neck

Biliary Tract Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms

NCT06640049 2025-11-17

China AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT05980416 2025-11-14

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Phase 1 Terminated

88 enrolled 18 charts

Gastrointestinal

Adenocarcinoma, Digestive System Neoplasms, Gastrointestinal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms

NCT06521567 2025-11-12

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Phase 1/2 Active not recruiting

CNSDermatologicGastrointestinalLymphoidSarcoma

Fibrolamellar hepatocellular carcinoma, Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Carcinoma, Hepatocellular, Hodgkin Disease, Melanoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma

NCT02817633 2025-10-28

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Phase 1 Active not recruiting

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04409002 2025-08-15

Niraparib + Dostarlimab + RT in Pancreatic Cancer

Phase 2 Completed

18 enrolled 11 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04493060 2025-08-07

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Phase 2 Completed

22 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Phase 1/2 Terminated

Gastrointestinal

Rectal Neoplasms

NCT05239546 2025-05-25

NAIO

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT06757244 2025-03-18

DOVIPA

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06762405 2025-02-18

PREDIR-NEOREC

Phase 3 Recruiting

GastrointestinalOther solid neoplasm

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Phase 2 Withdrawn

GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT06059495 2024-02-05

DEWI

Phase 2 Recruiting

Gastrointestinal

Adenocarcinoma - GEJ

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma